Trending...
- California: Governor Newsom announces appointments 3.20.2026
- Snell & Wilmer Recognized Among the Top 10 Largest Law Firms in Orange County by the OCBJ
- California announces 300 wildfire projects fast-tracked in 300 days
SANTA CLARA, Calif., July 22, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global RNA Therapeutics: Technology Growth Opportunities, reveals that ribonucleic acid (RNA) therapeutics is poised to gain momentum in the next few years and can potentially be applied to a wide variety of disease interventions. Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).
For further information on this analysis, please visit: http://frost.ly/62g
"Advances in RNA stability, manufacturing, chemical modification, and targeted delivery systems have led to the commercial translation of RNA therapeutics," said Ruplekha Choudhurie, TechVision Industry Analyst at Frost & Sullivan. "RNAs are relatively easy to manufacture, cost-effective, and can act on undruggable targets. As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies."
More on The Californer
- TCVN & CloneForce bring Agentic AI Pitch to Survivor 13 at Octane's OC Innovation Week at UCI
- Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
- New Book Reveals The Science Of Predictions
- Governor Newsom calls FCC Chair Brendan Carr a "disgrace," says California will lead more antitrust enforcement to protect consumers from Trump's rising costs
- California doubles down on ocean health with historic investments, following landmark report findings
Choudhurie added: "RNAs have certain advantages over deoxyribonucleic acid (DNA) and small molecule drugs, such as eliminating the risk of genomic integration, being relatively cost-effective, and having rapid development and production. Hence, RNA therapeutics investment has a better chance of commercial success and enables better returns in less time for market participants. Specifically, for the development of vaccines for COVID-19 and other emerging infectious disease outbreaks, mRNA vaccines have an advantage over other types of vaccines as they can be rapidly developed and amenable to modifications to target evolving viral variants."
The advantages of RNA therapeutics over conventional small molecule drugs and other biological drugs present immense growth opportunities for market players, including:
- Formulation and delivery of RNA therapeutics: Lipid-nanoparticles were used for delivery formulation in the previously approved RNA therapeutics, and similar (RNA-LNPs) formulations have been considered standard. Rapid formulation and delivery advances will improve the future of RNA delivery and help overcome the intrinsic stability issues of RNA.
- Stability of mRNA vaccines and RNA therapeutics at ambient temperature: Novel formulations that improve mRNA stability at ambient temperatures would facilitate the worldwide application of mRNA vaccines more rapidly and at a much lower cost. This will benefit mRNA vaccines and the entire RNA therapeutics field in general.
- mRNA vaccines and active participation of big pharmaceutical companies: Currently, RNA therapeutics is one of the fastest and most promising approaches in biological therapeutics. Due to this, many stakeholders are investing heavily in mRNA vaccines.
Global RNA Therapeutics: Technology Growth Opportunities is the latest addition to Frost & Sullivan's TechVision research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.
More on The Californer
- New Dosio App Helps GLP-1 Users Track Shots, Side Effects, and Weight Trends
- Rachel Farris, CPA and Founder of Tax Stack AI, Featured on The Big 4 Transparency Podcast
- Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews
- When the Wrong Word Can Cost Everything, You Need a Legal Translation Partner You Can Actually Trust
- News you won't see on Fox News: California revoked over 280 hospice licenses, 300 more providers under investigation since Governor Newsom's hospice moratorium
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Global RNA Therapeutics: Technology Growth Opportunities
DA00
Contact:
Mariana Fernandez
Corporate Communications
E: [email protected]
http://ww2.frost.com
SOURCE Frost & Sullivan
Related Links
www.frost.com
Filed Under: Business
0 Comments
Latest on The Californer
- California Housing Crisis Sparks Growth: Dave Simmons and StrataX Development Double Down on ADU Expansion
- California and European Commission discuss cooperation to accelerate the global transition to a carbon-neutral, resilient, and equitable future
- California Lutheran University Expands Board of Regents
- KeysCaribbean Offers 'Skip-the-Crowds' Savings With 15 Percent Off April Stays
- California: Governor Newsom announces appointments 3.23.2026
- Breaking the Civilian Barrier: ResuModAI Helps Veterans Translate Military Service into Job Offers in 60 Seconds
- Global Leaders Meet in Baku: The World Is Running Out of Time
- Long Beach Parks, Recreation and Marine to Offer Youth Summer Day Camps
- USFITC Extends International Defense Supply Capabilities with Sealing Component Delivery
- Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award
- For Financial Literacy Month: Check out "TINA, TARA, TAPAS & TIARA" & "Better Than Expected Losses"
- Benchmark International Successfully Facilitated the Transaction Between LPAS, Inc. and Bluwatr
- TIME WASTED: The 2027 Releasing TV Show
- JetPipe Plumbing Brings Licensed, Specialized Plumbing Services to the San Francisco Bay Area
- AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
- Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
- A-One Janitorial Wins $152M AI Campus Contract — Meta, Microsoft, Google, and AWS
- New Global Standard for Transparency Across Critical Resources and Energy Markets: SMX (Security Matters) PLC (N A S D A Q: SMX)
- Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
- Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)